← Back to Clinical Trials
Recruiting NCT05120518

NCT05120518 Post Mortem Tissue Donation of Pediatric Tumor Tissues and Cells

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05120518
Status Recruiting
Phase
Sponsor Ann & Robert H Lurie Children's Hospital of Chicago
Condition Pediatric Cancer
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2019-08-14
Primary Completion 2029-08-14

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Collection of post mortem tissue donation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2019-08-14 with a primary completion date of 2029-08-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this study is to utilize all donated pediatric tumor tissues and cells obtained from autopsy to prospectively develop novel patient derived orthotopic xenograft (PDOX) mouse models as well as in vitro cell culture model systems for pediatric cancers, and also provide tissue samples to other researchers and organizations (eg, CBTN, DIPG Registry, COG).

Eligibility Criteria

Inclusion Criteria: * Pediatric patients with cancer and non-cancer tumor types (solid, liquid, neuro-oncology) * Signed consent for post mortem tissue donation and autopsy Exclusion Criteria: * Signed consent for post mortem tissue donation and autopsy not obtained

Contact & Investigator

Central Contact

Angela Waanders, MD

✉ awaanders@luriechildrens.org

📞 312-227-4090

Principal Investigator

Angela Waanders, MD

PRINCIPAL INVESTIGATOR

Ann & Robert H Lurie Children's Hospital of Chicago

Frequently Asked Questions

Who can join the NCT05120518 clinical trial?

This trial is open to participants of all sexes, studying Pediatric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05120518 currently recruiting?

Yes, NCT05120518 is actively recruiting participants. Contact the research team at awaanders@luriechildrens.org for enrollment information.

Where is the NCT05120518 trial being conducted?

This trial is being conducted at Chicago, United States.

Who is sponsoring the NCT05120518 clinical trial?

NCT05120518 is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. The principal investigator is Angela Waanders, MD at Ann & Robert H Lurie Children's Hospital of Chicago. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology